Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel

Uteroglobin: a potential novel tumor suppressor and molecular therapeutic for prostate cancer.

Publication ,  Journal Article
Patierno, SR; Manyak, MJ; Fernandez, PM; Baker, A; Weeraratna, AT; Chou, DS; Szlyk, G; Geib, KS; Walsh, C; Patteras, J
Published in: Clin Prostate Cancer
September 2002

Currently, there are very few diagnostic or therapeutic strategies targeted at controlling tumor growth and progression towards metastasis. Uteroglobin (UG) is a naturally occurring, small, stable, secretory protein that is normally expressed by most cells of epithelial origin but is known to be lost during the progression of prostate, lung, and uterine cancers to invasive malignancy. Uteroglobin -/- knockout mice appear to be extremely cancer prone. Both pharmacological and transgenic reconstitution of recombinant human UG (rhUG) to prostate, lung, and endometrial tumor cell lines markedly inhibits their invasiveness and antagonizes the neoplastic phenotype. In preliminary studies, rhUG inhibited angiogenesis in the ex vivo rat aorta model and showed antitumor activity against human prostate tumor cells (PC-3) in the chick chorioallantoic membrane assay, reducing both tumor volume and vascularity. A recent in vivo pilot study showed that twice daily dosing with rhUG resulted in a statistically significant increase in survival without evidence of toxicity in severe combined immunodeficient mice challenged with a PC-3 cell metastasizing tumor. Thus, rhUG may slow the progression of cancer by inhibiting both tumor cell invasiveness and tumor angiogenesis. It therefore holds the potential to serve as a new weapon in the arsenal of cytostatic, antimetastatic, adjuvant treatment for cancer. In this paper, we will briefly discuss the therapeutic potential of uteroglobin-based strategies for managing prostate cancer.

Duke Scholars

Published In

Clin Prostate Cancer

DOI

ISSN

1540-0352

Publication Date

September 2002

Volume

1

Issue

2

Start / End Page

118 / 124

Location

United States

Related Subject Headings

  • Uteroglobin
  • Tumor Cells, Cultured
  • Survival Rate
  • Sensitivity and Specificity
  • Rats
  • Prostatic Neoplasms
  • Prognosis
  • Pilot Projects
  • Oncology & Carcinogenesis
  • Mice, Transgenic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Patierno, S. R., Manyak, M. J., Fernandez, P. M., Baker, A., Weeraratna, A. T., Chou, D. S., … Patteras, J. (2002). Uteroglobin: a potential novel tumor suppressor and molecular therapeutic for prostate cancer. Clin Prostate Cancer, 1(2), 118–124. https://doi.org/10.3816/cgc.2002.n.014
Patierno, Steven R., Michael J. Manyak, Patricia M. Fernandez, Angela Baker, Ashani T. Weeraratna, David S. Chou, Greg Szlyk, K Shane Geib, Christopher Walsh, and John Patteras. “Uteroglobin: a potential novel tumor suppressor and molecular therapeutic for prostate cancer.Clin Prostate Cancer 1, no. 2 (September 2002): 118–24. https://doi.org/10.3816/cgc.2002.n.014.
Patierno SR, Manyak MJ, Fernandez PM, Baker A, Weeraratna AT, Chou DS, et al. Uteroglobin: a potential novel tumor suppressor and molecular therapeutic for prostate cancer. Clin Prostate Cancer. 2002 Sep;1(2):118–24.
Patierno, Steven R., et al. “Uteroglobin: a potential novel tumor suppressor and molecular therapeutic for prostate cancer.Clin Prostate Cancer, vol. 1, no. 2, Sept. 2002, pp. 118–24. Pubmed, doi:10.3816/cgc.2002.n.014.
Patierno SR, Manyak MJ, Fernandez PM, Baker A, Weeraratna AT, Chou DS, Szlyk G, Geib KS, Walsh C, Patteras J. Uteroglobin: a potential novel tumor suppressor and molecular therapeutic for prostate cancer. Clin Prostate Cancer. 2002 Sep;1(2):118–124.

Published In

Clin Prostate Cancer

DOI

ISSN

1540-0352

Publication Date

September 2002

Volume

1

Issue

2

Start / End Page

118 / 124

Location

United States

Related Subject Headings

  • Uteroglobin
  • Tumor Cells, Cultured
  • Survival Rate
  • Sensitivity and Specificity
  • Rats
  • Prostatic Neoplasms
  • Prognosis
  • Pilot Projects
  • Oncology & Carcinogenesis
  • Mice, Transgenic